Previous 10 | Next 10 |
RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops sp...
RAMSEY, N.J. and BOCA RATON, Fla., May 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops sp...
ADMA stock has just received a consensus rating of “Buy” from nine brokerages covering the stock. With all in agreement, why are analysts bullish on this biotechnology stock? Let’s find out! AMDA Stock Selling for $4.53 at present on the NASDAQ exchange, ADMA Biol...
The USPTO has issued ADMA Biologics' (NASDAQ: ADMA ) Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection. More news on: ADMA Biologics, Inc., Healthcare stocks news, Read more ...
RAMSEY, N.J. and BOCA RATON, Fla., April 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to met...
RAMSEY, N.J. and BOCA RATON, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops ...
Gainers: AVEO Pharmaceuticals (NASDAQ: AVEO ) +35% . ADMA Biologics (NASDAQ: ADMA ) +32% . Sangamo Therapeutics (NASDAQ: SGMO ) +27% . Castor Maritime (NASDAQ: CTRM ) +24% . EDAP TMS S.A. (NASDAQ: EDAP ) +23% . Riot Blockchain (NASDAQ: RIOT ) +22% . Vaccinex (NASDAQ: VCNX ) +1...
ADMA Biologics (NASDAQ: ADMA ) +46% as FDA approves ADMA Biologics' ASCENIV. More news on: ADMA Biologics, Inc., Sangamo Therapeutics, Inc., Riot Blockchain, Inc., Stocks on the move, Read more ...
The FDA has approved ADMA Biologics' (NASDAQ: ADMA ) ASCENIV, Immune Globulin Intravenous, Human – slra 10% Liquid, formerly referred to as RI-002. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Approved for Use in the Treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in Adults and Adolescents (12 to 17 Years of Age) FDA Approval Triggers Funding up to $27.5M from Existing Credit Facility with Perceptive Advisors RAMSEY, N.J. ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...